Answers are grounded in this paper and cite their sources.
Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.)
No takes yet. Share an insight, caveat, or question.
Saglio et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: